← Back to Home

Cancer Antibodies Enter the Era of Wearable Administration, as FDA Approval Pushes Devices to the Front Line

Sanofi’s Sarclisa Escena has been approved in the United States for administration with an on-body injector, extending the innovation focus in multiple myeloma treatment from the drug itself to the delivery system worn by the patient.

By SURL BioNews

The burden of cancer treatment often comes not only from drug toxicity, but also from the accumulated time spent on repeated hospital visits, waiting, infusions, and monitoring. The U.S. FDA’s approval of Sanofi’s subcutaneous version of Sarclisa Escena for the existing intravenous Sarclisa indications in multiple myeloma means the real novelty is not merely that an antibody has changed its route of administration, but that, for the first time in the United States, an anticancer drug has been brought into routine clinical use with delivery by an on-body injector.

Sanofi said Sarclisa Escena contains isatuximab-irfc and can be used in combination with standard-of-care regimens, covering the current multiple myeloma indications for intravenous Sarclisa. The approval also includes two methods of subcutaneous administration: manual subcutaneous injection by healthcare professionals, and administration through Enable Injections’ on-body injector system. Enable, meanwhile, positions its enFuse platform as a wearable, high-volume subcutaneous drug delivery system suitable for larger-volume biologics.

One of the key pieces of evidence supporting the approval was the IRAKLIA Phase 3 non-inferiority trial. Data released by Sanofi showed that the group receiving subcutaneous Sarclisa in combination with pomalidomide and dexamethasone, administered with an on-body injector, had an objective response rate of 71.1%; the group receiving intravenous Sarclisa with the same drugs had a rate of 70.5%. The company also noted fewer systemic administration reactions in the subcutaneous group. However, these figures mainly show comparable efficacy after switching the route of administration, and do not mean that there is already a new advantage in disease control or survival outcomes.

For clinical settings, the significance of device-based administration lies in reallocating care time. Patients with multiple myeloma often receive long-term, repeated treatment. If some infusion processes can be shortened into subcutaneous administration, patients’ time spent in hospital, use of infusion chairs, and nursing schedules may all change. But this kind of change will also place new responsibilities on device reliability, administration training, prevention of medication errors, and arrangements for post-administration monitoring.

Background

The European Commission already approved the same subcutaneous Sarclisa regimen in June 2026. At the time, Sanofi described it as the EU’s first anticancer treatment that can be administered through both an on-body injector and manual subcutaneous injection. The U.S. approval takes this pathway across another major regulatory market, and also brings combination products involving drugs and delivery devices more clearly into mainstream discussion in oncology treatment.

This is not a sudden breakthrough in curative strategies for multiple myeloma, but a redesign of a mature antibody therapy in formulation and care workflows. The next real test will be whether hospitals can smoothly embed device-based administration into workflows, how insurance and reimbursement will view the cost of the new formulation, and whether patients undergoing long-term treatment truly experience a lower burden of time and care.

References

  1. Drug Delivery Business
  2. Sanofi
  3. Enable Injections
  4. Sanofi